Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Drossman, W. Thompson (1992)
The irritable bowel syndrome: review and a graduated multicomponent treatment approach.Annals of internal medicine, 116 12 Pt 1
Camilleri (2000)
331Pharmacoeconomics, 17
M. Lefkowitz, Peter Rueegg, Yingqi Shi, Cornelia Baldauf (2000)
Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserodGastroenterology, 118
J. Fioramonti, M. Million, L. Buéno (1998)
Investigations on a 5HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptying*Gastroenterology, 114
K. Klein (1988)
Controlled treatment trials in the irritable bowel syndrome: a critique.Gastroenterology, 95 1
J. Grider, A. Foxx-Orenstein, Ji-Guang Jin (1998)
5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.Gastroenterology, 115 2
M. Schmulson, O. Lee, Lin Chang, B. Naliboff, E. Mayer (1999)
Symptom differences in moderate to severe IBS patients based on predominant bowel habitAmerican Journal of Gastroenterology, 94
M. Farthing (1999)
Irritable bowel syndrome: new pharmaceutical approaches to treatment.Bailliere's best practice & research. Clinical gastroenterology, 13 3
S. Zanten, J. Talley, P. Bytzer, B. Klein, J. Whorwell, A. Zinsmeister, RomeII, N. Talley, K. Klein, S. Velduyzen, van Zanten (1999)
Design of treatment trials for functional gastrointestinal disordersGut, 45
S. Hegde, R. Eglen (1996)
Peripheral 5‐HT4 receptorsThe FASEB Journal, 10
A. Coelho, P. Rovira, J. Fioramonti, L. Buéno (2000)
Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in ratsGastroenterology, 118
François Puisieux, M. Adamantidis, B. Dumotier, B. Dupuis (1996)
Cisapride‐induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibresBritish Journal of Pharmacology, 117
S. Appel, A. Kumle, R. Meier (1997)
Clinical pharmacodynamics of SDZ HTF 919, a new 5‐HT4 receptor agonist, in a model of slow colonic transitClinical Pharmacology & Therapeutics, 62
J. Kellow, Michel Delvaux, Fernando Azpiroz, Michael Camilleri, E. Quigley, David Thompson (1999)
Principles of applied neurogastroenterology: physiology/motility–sensationGut, 45
Bradette Bradette, Delvaux Delvaux, Staumont Staumont, Fioramonti Fioramonti, Bueno Bueno, Frexinos Frexinos (1994)
Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle toneDig Dis Sci, 39
H. Baumgarten, M. Göthert (2000)
Serotoninergic Neurons and 5-HT Receptors in the CNS
(1988)
Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in intestinal motility disorders
MD Muller-Lissner, Zicmssenstr Inncnstadt, Ncufahrn Boehm, D. Schulz-Mcrkel, H. KemptenM, Bouzo, G. Augsburg, Mfinchcn Vorbcrg, Dcttmcr, H. Muinchen, Steinh6ring Zimmer, Hanisch, M. Kauflcurcn, Munchen Philippi (1987)
Treatment of chronic constipation with cisapride and placebo.Gut, 28
W. Whitehead, O. Palsson (1998)
Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception.Gastroenterology, 115 5
K. Schütze, G. Brandstätter, B. Dragosics, G. Judmaier, E. Hentschel (1997)
Double‐blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 11
J. Everhart, P. Renault (1991)
Irritable bowel syndrome in office-based practice in the United States.Gastroenterology, 100 4
Whitehead (1996)
2248Dig Dis Sci, 41
D. Drossman (1994)
The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment : A Multinational Consensus
C. Prather, M. Camilleri, A. Zinsmeister, S. Mckinzie, G. Thomforde (2000)
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.Gastroenterology, 118 3
Sergio Bran, William Murray, Irl Hirsch, Jerry Palmer (1995)
Long QT syndrome during high-dose cisapride.Archives of internal medicine, 155 7
(1995)
The properties of a new prokinetically active drug, SDZ HTF 919
M. Outryve, R. Milo, J. Toussaint, P. Eeghem (1991)
"Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride.Journal of clinical gastroenterology, 13 1
A. Nguyen, M. Camilleri, L. Kost, Alejandro Metzger, Michel Sarr, R. Hanson, S. Fett, A. Zinsmeister (1997)
SDZ HTF 919 stimulates canine colonic motility and transit in vivo.The Journal of pharmacology and experimental therapeutics, 280 3
M. Karaus, M. Wienbeck (1991)
Colonic motility in humans--a growing understanding.Bailliere's clinical gastroenterology, 5 2
C. Hawkey (1999)
Irritable bowel syndrome clinical trial design: future needs.The American journal of medicine, 107 5A
N. Talley, O. Nyrén, D. Drossman, K. Heaton, S. Zanten, M. Koch, D. Ransohoff (1993)
The irritable bowel syndrome: Toward optimal design of controlled treatment trials, 6
(1999)
Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist
J. Bockaert, L. Fagni, A. Dumuis (2000)
5-HT4 Receptors: An UpdateHandbook of experimental pharmacology, 129
Camilleri Camilleri, Williams Williams (2000)
Economic burden of irritable bowel syndrome: proposed strategies to control expendituresPharmacoeconomics, 17
B. Hahn, Songkai Yan, S. Strassels (1999)
Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United KingdomDigestion, 60
M. Camilleri, Myung-Gyu Choi (1997)
Review article: irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 11
(2000)
The 5-HT4 receptor agonist tegaserod (HTF 919) accelerates upper and lower gastrointestinal (GI) transit
K. Buchheit, R. Gamse, R. Giger, D. Hoyer, F. Klein, E. Klöppner, H. Pfannkuche, H. Mattes (1995)
The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists.Journal of medicinal chemistry, 38 13
Whitehead Whitehead, Burnett Burnett, Cook Cook, Taub Taub (1996)
Impact of irritable bowel syndrome on quality of lifeDig Dis Sci, 41
R. Spiller (1999)
Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials.The American journal of medicine, 107 5A
Thompson Thompson, Creed Creed, Drossman Drossman, Heaton Heaton, Mazzacca Mazzacca (1992)
Functional bowel disease and functional abdominal painGastroenterol Int, 5
W. Thompson, G. Longstreth, D. Drossman, W. Heaton, J. Irvine, A. Müller-Lissner, S. Müller-lissner, MD Thompson (1999)
Functional bowel disorders and functional abdominal painGut, 45
Aim: To investigate the efficacy and safety of tegaserod, a novel 5‐HT4 receptor partial agonist, in a randomized, double‐blind, placebo‐controlled, 12‐week treatment, multicentre study. Methods: Eight hundred and eighty‐one patients with irritable bowel syndrome, characterized by abdominal pain, bloating and constipation, received tegaserod, 2 mg b.d. or 6 mg b.d., or placebo for 12 weeks. Results: Tegaserod, 2 mg b.d. and 6 mg b.d., showed a statistically significant relief of overall irritable bowel syndrome symptoms, measured by a weekly, self‐administered questionnaire. At end‐point, treatment differences from placebo were 12.7% and 11.8% for 2 mg b.d. and 6 mg b.d., respectively. The effect of tegaserod was noted as early as week 1, and was sustained over the 12‐week treatment period. Individual irritable bowel syndrome symptoms assessed daily also showed a statistically significant improvement of abdominal discomfort/pain, number of bowel movements and stool consistency, and a favourable trend for reducing days with significant bloating. Adverse events were similar in all groups, with transient diarrhoea being the only adverse event seen more frequently with tegaserod than placebo. Conclusions: Based upon the results of this study, tegaserod offers rapid and sustained relief of the abdominal pain and constipation associated with irritable bowel syndrome. Tegaserod is also well tolerated.
Alimentary Pharmacology & Therapeutics – Wiley
Published: Oct 2, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.